Silence Therapeutics signs collaboration with miRagen Therapeutics to evaluate delivery of novel microRNA-based therapeutics

11-Jan-2012 - United Kingdom

Silence Therapeutics plc announced that it has signed an agreement with miRagen Therapeutics, Inc. to assess the delivery potential of Silence’s proprietary DBTC delivery system with miRagen’s novel microRNA- (miRNA-) based therapeutics. 

Under the terms of the agreement, miRagen will provide Silence with specific miRNA sequences, which Silence will formulate with its proprietary DBTC delivery system in order to develop multiple candidate drugs. MiRagen will undertake in vitro and in vivo studies of the candidate drugs developed under the agreement and select lead candidates for further evaluation. Financial terms of the collaboration are not disclosed.

DBTC is a proprietary RNAi delivery system developed by Silence. It is a novel lipid-based formulation that functionally delivers short interfering RNA (siRNA) to liver endothelial cells, hepatocytes and other liver cell types with high efficiency.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances